Chester County News and Community Website
MALVERN, PA — Endo, a subsidiary of Mallinckrodt plc, has expanded its ADRENALIN® line with the launch of three new FDA-approved premixed intravenous (IV) bag concentrations: 2 mg/250 mL, 5 …
Endo Expands ADRENALIN® Portfolio With New FDA-Approved Premixed IV Bags Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will expand development of its investigational therapy QTORIN™ 3.9% rapamycin anhydrous gel into clinically significant angiokeratomas, a rare and debilitating …
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas Read More
WASHINGTON, D.C. — The U.S. Department of Health and Human Services announced more than $1.5 billion in new funding and a series of initiatives last week aimed at tackling the …
HHS Unveils Sweeping Actions on Opioids, Autism, Tribal Care, and Nutrition Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a newly developed crystal form of buntanetap, its …
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug Read More
WASHINGTON, D.C. — The Food and Drug Administration unveiled a series of high-profile actions last week, ranging from a potential new therapy for autism symptoms to a landmark approval of …
FDA Weighs Autism Drug, Pregnancy Risk Warning, and First Glasses to Slow Myopia Read More
WASHINGTON, D.C. — The Centers for Disease Control and Prevention issued a series of public health updates last week, reporting a steep rise in dangerous drug-resistant bacteria, troubling increases in …
CDC Warns of Drug-Resistant Bacteria Surge, Rising Syphilis in Newborns, and Listeria Outbreak Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has completed TOIVA, a Phase 2 proof-of-concept trial of QTORIN™ 3.9% rapamycin anhydrous gel, for the treatment of cutaneous venous …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has published new research in the journal Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, its lead drug …
Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has completed TOIVA, its Phase 2 clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel as a potential treatment for cutaneous venous malformations …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder Read More
PHILADELPHIA, PA — Penn Medicine, in collaboration with the Young Chances Foundation, will host The Huddle: A Community Conversation on Men’s Mental Health on Tuesday, September 23, 2025, from 5:30 …
Penn Medicine and Young Chances Foundation to Host Men’s Mental Health Event in Philadelphia Read More